Kratom half-life
The model is specifically a mitragynine terminal-phase reference drawn from small human studies, not a half-life for the whole kratom plant.
Every curve begins at 100%. No dose or measured body concentration is assumed.
X-axis: elapsed time. Y-axis: modeled percentage of the relative starting point remaining. This is a mathematical visualization, not a personal concentration estimate.
Kratom: evidence and interpretation notes
What the representative value means
The model is specifically a mitragynine terminal-phase reference drawn from small human studies, not a half-life for the whole kratom plant. Other alkaloids in the same product showed materially different distribution and terminal behavior.
The plotted input is 23 hours for Kratom. It is a normalized comparison line, not a reconstruction of a measured blood concentration or a forecast of effects.
Kratom is represented through mitragynine-centered pharmacokinetic sources, because kratom products are botanicals rather than a single standardized drug product.
The 23 hour value creates a long curve relative to many entries. Product composition, alkaloid ratios, and individual metabolism can make real exposures more variable than the chart suggests.
The citations include human mitragynine pharmacokinetics, a controlled kratom pharmacokinetic assessment, and the mitragynine compound record.
This page does not evaluate product quality, dependence risk, treatment, or safety.
For Kratom, product variability and alkaloid composition make the curve less definitive than a prescription label. The page is best used to understand the selected mitragynine-centered estimate.
What each source contributes
- Trakulsrichai S et al. Pharmacokinetics of mitragynine in man (2015). This human pharmacokinetic record adds measured route, analyte, and population context and does not become a universal result.
- Tanna RS et al. Clinical pharmacokinetic assessment of kratom in healthy adults (2022). This human pharmacokinetic record adds measured route, analyte, and population context and does not become a universal result.
- PubChem: Mitragynine. This identity record confirms names and compound identity and does not supply a human half-life.
For Kratom, the numerical model is tied most closely to Trakulsrichai S et al. Pharmacokinetics of mitragynine in man (2015). As a human pharmacokinetic record, it adds measured route, analyte, and population context; it does not become a universal result.
Why there is no range on the chart
This profile plots 23 hours for Kratom without adding an unsourced high-low band. A single supported center is more honest than manufacturing a range from unrelated routes, populations, or formulations.
InterpretationReading the curve and its category context
Reading this curve
HalfLifeDB uses 23 h as a representative input for Kratom. In the simplified model, about 48.5% remains after 24 hours and about 3% remains after five half-lives, or roughly 4.8 days.
This is a day-scale half-life. Repeated exposure, timing, and source context start to matter more than a single snapshot of the curve. The curve is relative: it does not estimate a person's measured concentration, effects, impairment, or time to clearance.
atypical opioid context
Atypical opioid entries can involve parent compounds, active metabolites, and non-opioid pharmacology that make duration and risk diverge from one half-life number.
- The curve is not a respiratory-risk, withdrawal, or analgesia-duration estimate.
- Metabolites and enzyme differences can change interpretation.
- Clinical and toxicology questions require source-specific context.
ComparisonTimeline checkpoints and nearby profiles
Kratom timeline checkpoints
| Elapsed time | Modeled remaining | Reading note |
|---|---|---|
| 12 h | 69.7% | Meaningful modeled decline, not near-zero |
| 24 h | 48.5% | Meaningful modeled decline, not near-zero |
| 2.0 days | 23.5% | Long-tail portion of the model |
| 3.0 days | 11.4% | Long-tail portion of the model |
| 5.0 days | 2.69% | Low modeled remainder, not a clearance guarantee |
Nearby profiles by half-life
These entries sit near Kratom within the atypical opioid group when sorted by representative half-life. That makes them curve comparisons, not statements about equal potency, effects, or risk.
No nearby published profiles are available in this category.
EvidencePharmacokinetic inputs and source trail
Pharmacokinetics at a glance
| Representative half-life | 23 h |
|---|---|
| Curve type | Normalized, first-order decline |
Selection note: The model is specifically a mitragynine terminal-phase reference drawn from small human studies, not a half-life for the whole kratom plant. Other alkaloids in the same product showed materially different distribution and terminal behavior.
Sources and evidence context
A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.
- Research abstract Trakulsrichai S et al. Pharmacokinetics of mitragynine in man (2015).Direct pharmacokinetic context. Population, route, formulation, analyte, and sampling duration still determine how broadly the result can be applied.
- Research abstract Tanna RS et al. Clinical pharmacokinetic assessment of kratom in healthy adults (2022).Direct pharmacokinetic context. Population, route, formulation, analyte, and sampling duration still determine how broadly the result can be applied.
- Identity record PubChem Compound Summary: Mitragynine.Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
BoundariesWhat this page cannot answer and where to continue
What this page does not answer
- It does not estimate impairment, intoxication, or fitness to drive.
- It does not predict urine, blood, saliva, or hair test results.
- It does not model repeated exposure, tolerance, withdrawal, or interactions.
- It does not replace clinician, pharmacist, toxicologist, or emergency guidance.
Continue with context
- All substance profiles
- Browse the atypical-opioid group
- Compare this curve
- Clearance and volume of distribution
- Bioavailability, route, and formulation
- Active metabolites and parent compounds
- First-order vs nonlinear kinetics
- Detection windows vs half-life
- Reading labels and source quality
Read the medical disclaimer, methodology, and research standards before using the model for comparison.